肿瘤药学2025，Vol.15Issue(2)：264-268,5.DOI:10.3969/j.issn.2095-1264.2025.02.16
安罗替尼联合AK105治疗一线复发的小细胞肺癌1例
Anlotinib combined with AK105 in the treatment of relapsed small cell lung cancer after first-line therapy:a case report
摘要
Abstract
This article reports a case of 65-year-old patient with limited-stage small cell lung cancer(LS-SCLC)who developed disease progression 5 months after completing first-line concurrent chemoradiotherapy(etoposide plus cisplatin with radiotherapy).After a thorough assessment,the patient was enrolled in a clinical trial that employed immune therapy combined with anti-angiogenic therapy,receiving anlotinib and penpulimab(AK105)every 21 days as a treatment cycle.After 40 cycles of therapy,the patient achieved partial response(PR)with a progression-free survival(PFS)of 29.5 months.Currently,there is a lack of effective regimens for later-line treatment of relapsed LS-SCLC,and its therapeutic strategies are more frequently overlooked compared to extensive-stage small cell lung cancer(ES-SCLC).The treatment plan for this patient provides valuable clinical insights for the management of relapsed LS-SCLC in later-line settings.关键词
小细胞肺癌/安罗替尼/派安普利单抗/病例报道Key words
Small cell lung cancer/Anlotinib/Penpulimab/Case report分类
临床医学引用本文复制引用
毕文欣,杜超,李成林..安罗替尼联合AK105治疗一线复发的小细胞肺癌1例[J].肿瘤药学,2025,15(2):264-268,5.基金项目
山东省自然科学基金项目(ZR2021MH183). （ZR2021MH183）
